Biosimilar humira?

Yes. Humira (adalimumab) has several biosimilars, designed to be highly similar to Humira and to treat the same conditions (like rheumatoid arthritis, Crohn’s/ulcerative colitis, psoriatic arthritis, etc.). Availability and exact names depend on country, but some well-known U.S. market biosimilars include:

- Amjevita (adalimumab-atto) — by Amgen
- Cyltezo (adalimumab-adbm) — by Boehringer Ingelheim
- Abrilada (adalimumab-adaz) — by Pfizer
- Idacio (adalimumab-fkjp) — by Viatris
- Hyrimoz (adalimumab-adaz) — by Sandoz (Novartis)

There are additional biosimilars in Europe and other regions (and new ones have been approved over time). They are intended to have the same safety and efficacy profile as Humira, with potential cost savings. However, they are not automatically interchangeable in all settings.

A few quick clarifying questions to tailor the info:
- Which country or region are you asking about?
- Are you interested in which biosimilars are designated interchangeable (allowing automatic substitution), or just which ones exist?
- Do you want info on cost/insurance or on switching from Humira to a biosimilar?

If you share your location and priorities, I can give you a country-specific list and current interchangeability/substitution status. Also I can discuss safety, dosing, and device differences if you’d like.